NovoCure

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure is a public oncology company with over 1,000 employees. The company has raised a total of $742 million across five funding rounds. In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing.

Business overview

NovoCure is a commercial-stage oncology company focused on developing and commercializing Tumor Treating Fields (TTFields) therapy for solid tumor cancers. This proprietary technology uses low-intensity, intermediate-frequency alternating electric fields to disrupt cell division in cancer cells. The therapy is delivered via noninvasive, insulated transducer arrays and a portable electric field generator, designed for continuous wear. NovoCure's products, including Optune Lua and Optune Gio, serve the healthcare market, specifically patients and providers in the oncology sector, with an FDA approval for metastatic non-small cell lung cancer.

Strategic signal

In September 2024, NovoCure announced a planned CEO transition, with Asaf Danziger retiring and CFO Ashley Cordova named as successor. This leadership change signals a strategic shift in the company's executive management, which could influence future operational direction and investor confidence, particularly as the company continues to advance its Tumor Treating Fields therapy.

Company Intelligence Q&A

What is NovoCure's primary technology?

NovoCure develops Tumor Treating Fields (TTFields) therapy, a proprietary technology that uses low-intensity, intermediate-frequency alternating electric fields to disrupt mitosis and cytokinesis in solid tumor cancers.

When did NovoCure go public?

NovoCure went public on NASDAQ in October 2015, raising $165 million with a valuation of $1.8 billion.

What was a significant recent financing event for NovoCure?

In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing from Pharmakon.

What recent leadership change occurred at NovoCure?

In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor.

Has NovoCure received any recent regulatory approvals for its products?

In September 2025, NovoCure's Optune Lua device received approval in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC).